BEAM News and Press, Beam Therapeutics Inc. From 01/29/24

2024-01-29 18:21:00 ET Beam Therapeutics (NASDAQ: BEAM) stock thundered out of the gate this week, rising to close nearly 17% higher in price on Monday. Much of this was due to a recommendation upgrade from a prominent bank. By contrast, the S&P 500 only eked out a 0.8% gain...

2024-01-29 14:48:44 ET More on Beam Therapeutics CRISPR Gene Editing: Beam Therapeutics Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision Biotechs post record gains in November amid improving outlook Gene editing stocks slide aft...

2024-01-28 00:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-25 10:57:50 ET Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsou...

2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...

2024-01-17 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for ...

2024-01-05 13:00:18 ET More on ARK Innovation ETF: ARKK: Not The Beta Play One May Hope For ARKK: Forget About Innovation And Focus On What The U.S. Treasury Does ARKK Set To Ride This Bull Market Higher Into 2024 Cathie Wood's ARK Invest sold 759K shares of ...

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, Jan...

2023-12-29 19:03:08 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Cell and gen...